Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NN1250 versus insulin glargine in insulin-naive adults with type 2 diabetes
2009-010662-28Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of insulin degludec and insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change from baseline in HbA1c after 26 weeks of treatment. Started Nov 2009; status: completed.
02
Drugs
insulin degludecinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-010662-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010662-28.